- Home
- PCYO vs MNPR Comparison
PCYO vs MNPR Comparison
Compare PCYO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- MNPR
- Stock Information
- Founded
- PCYO 1976
- MNPR 2014
- Country
- PCYO United States
- MNPR United States
- Employees
- PCYO N/A
- MNPR N/A
- Industry
- PCYO Water Supply
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- MNPR Health Care
- Exchange
- PCYO Nasdaq
- MNPR Nasdaq
- Market Cap
- PCYO 271.7M
- MNPR 244.1M
- IPO Year
- PCYO N/A
- MNPR 2019
- Fundamental
- Price
- PCYO $9.96
- MNPR $39.59
- Analyst Decision
- PCYO
- MNPR Strong Buy
- Analyst Count
- PCYO 0
- MNPR 5
- Target Price
- PCYO N/A
- MNPR $59.50
- AVG Volume (30 Days)
- PCYO 57.5K
- MNPR 27.1K
- Earning Date
- PCYO 04-09-2025
- MNPR 05-08-2025
- Dividend Yield
- PCYO N/A
- MNPR N/A
- EPS Growth
- PCYO 118.08
- MNPR N/A
- EPS
- PCYO 0.59
- MNPR N/A
- Revenue
- PCYO $29,911,000.00
- MNPR N/A
- Revenue This Year
- PCYO N/A
- MNPR N/A
- Revenue Next Year
- PCYO N/A
- MNPR N/A
- P/E Ratio
- PCYO $16.92
- MNPR N/A
- Revenue Growth
- PCYO 58.85
- MNPR N/A
- 52 Week Low
- PCYO $8.94
- MNPR $1.72
- 52 Week High
- PCYO $14.63
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- PCYO 39.80
- MNPR 57.10
- Support Level
- PCYO $9.81
- MNPR $26.06
- Resistance Level
- PCYO $11.14
- MNPR $40.90
- Average True Range (ATR)
- PCYO 0.48
- MNPR 4.78
- MACD
- PCYO -0.02
- MNPR 0.64
- Stochastic Oscillator
- PCYO 16.90
- MNPR 84.89
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. It designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The company's services include water production, storage, treatment, bulk transmission to retail distribution systems, wastewater collection and treatment, irrigation water treatment and transmission, construction management, billing, and collection. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.